BHST
BioHarvest Sciences Inc. Common StockBHST
BHST
About: BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. This company is the industrial large-scale plant cell growth technology capable of directly and constantly producing active plant ingredients without the necessity to grow the plant itself. The company is focused on leveraging its botanical synthesis technology to develop the next generation of science-based and clinical therapeutic solutions, within two business verticals - nutraceutical health and wellness products such as dietary supplements, and the development of plant cell-based Active Pharmaceutical Ingredients (APIs) that focus on specific medical indications.
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
0.51% more ownership
Funds ownership: 0% [Q3] → 0.51% (+0.51%) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for BHST.
Financial journalist opinion
Based on 8 articles about BHST published over the past 30 days
Positive
Proactive Investors
2 days ago
BioHarvest shares rise after Q4 results show strong demand for VINIA products
BioHarvest Sciences Inc. (NASDAQ:BHST) reported a 62% year-over-year increase in fourth-quarter revenue, reaching $7.3 million, as the biotechnology company saw strong demand for its VINIA product lines and expanded its contract development and manufacturing organization (CDMO) services. Full-year revenue nearly doubled to $25.2 million, with gross margins improving by 1,000 basis points to 55%.
Neutral
Seeking Alpha
2 days ago
BioHarvest Sciences Inc. (BHST) Q4 2024 Earnings Conference Call Transcript
BioHarvest Sciences Inc. (NASDAQ:BHST ) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants Ilan Sobel - CEO Bar Dichter - CFO Conference Call Participants Anthony Vendetti - Maxim Group Amit Dayal - H.C. Wainwright Hunter Diamond - Diamond Equity Research Susan Anderson - Canaccord Operator Greetings, and welcome to the BioHarvest Sciences Fourth Quarter 2024 Corporate Update Conference Call.
Negative
Zacks Investment Research
2 days ago
BioHarvest Sciences Inc. (BHST) Reports Q4 Loss, Lags Revenue Estimates
BioHarvest Sciences Inc. (BHST) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.70 per share a year ago.
Neutral
Newsfile Corp
2 days ago
BioHarvest Sciences Reports Fourth Quarter and Full Year 2024 Financial Results
Fourth Quarter Revenues Grew 62% to $7.3 Million, Exceeding Prior Management Guidance, with Full Year Revenues Increasing 99% Year-Over-Year to $25.2 Million CDMO Division Secures Anchor Partnership with Tate & Lyle to Develop Next Generation of Plant-Based Sweeteners Rehovot, Israel--(Newsfile Corp. - March 31, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 & Subsequent Operational Highlights All figures stated in this news release are in U.S. dollars unless stated otherwise.
Positive
Zacks Investment Research
2 weeks ago
Strength Seen in BioHarvest Sciences Inc. (BHST): Can Its 12.7% Jump Turn into More Strength?
BioHarvest Sciences Inc. (BHST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Neutral
Newsfile Corp
2 weeks ago
BioHarvest Sciences to Host Fourth Quarter and Full Year 2024 Earnings Call on March 31 at 4:30 p.m. Eastern Time
Rehovot, Israel--(Newsfile Corp. - March 17, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it will release financial results for the fourth quarter and full year ended December 31, 2024 after market close on Monday, March 31, 2025. Management will host an investor conference call and webcast at 4:30 p.m.
Neutral
Newsfile Corp
4 weeks ago
BioHarvest Sciences to Participate in 37th Annual Roth Conference on March 16-18, 2025
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 6, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that management has been invited to attend the 37th Annual Roth Conference taking place on March 16-18, 2025. CEO Ilan Sobel is scheduled to host one-on-one meetings with institutional investors throughout the duration of the event.
Neutral
Newsfile Corp
4 weeks ago
BioHarvest In Vitro Testing Shows Proprietary Olive Cell Compound Reduces Fat Accumulation in Liver Cells
Non-Alcoholic Fatty Liver Disease (NAFLD) Affects 30-40% of U.S. Adults, Driving Significant Market Need for BioHarvest's Future Olive Cell Product Targeting Liver Health Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 4, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology process, today announced new 'in vitro' test results for the Company's proprietary new Olive Cell compound, which showed reduced fat accumulation in human liver cells. Fat accumulation in the liver is a leading cause of non-alcohol fatty liver disease (NAFLD), which affects 30-40% of U.S. adults*.
Neutral
Newsfile Corp
1 month ago
BioHarvest Announces Sales of Flagship Product VINIA Now Exceed $50 Million USD
Commercial success of VINIA validates the power of BioHarvest's patented Botanical Synthesis technology to produce valuable plant-based Compounds at industrial scale Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - February 18, 2025) - BioHarvest Sciences Inc. , (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology process, today announced that its Red Grape Cell composition - known commercially as VINIA® - has now exceeded $50 Million USD in cumulative sales with the vast majority of sales occurring since launching in the US less than 4 years ago. VINIA®, a red grape cell-based supplement, is produced by BioHarvest's proprietary Botanical Synthesis platform technology.
Neutral
Newsfile Corp
1 month ago
BioHarvest Sciences to Present at WeBull Consumer Stocks Webinar on February 18
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - February 12, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (CSE: BHSC) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that management has been invited to present at the WeBull Consumer Stocks Virtual Webinar taking place on February 18, 2025. CEO Ilan Sobel is scheduled to present at the event.
Charts implemented using Lightweight Charts™